These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 19298766

  • 1. Use of biologic therapeutics in difficult-to-treat psoriasis.
    Lynde C.
    J Cutan Med Surg; 2009; 13(1):6-17. PubMed ID: 19298766
    [Abstract] [Full Text] [Related]

  • 2. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM.
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [Abstract] [Full Text] [Related]

  • 4. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP.
    Ned Tijdschr Geneeskd; 2006 May 13; 150(19):1065-70. PubMed ID: 16733982
    [Abstract] [Full Text] [Related]

  • 5. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM, Saini R, Tutrone WD.
    J Drugs Dermatol; 2002 Dec 13; 1(3):303-10. PubMed ID: 12851990
    [Abstract] [Full Text] [Related]

  • 6. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
    Langley RG, Ho V, Lynde C, Papp KA, Poulin Y, Shear N, Toole J, Zip C.
    J Cutan Med Surg; 2006 Dec 13; 9 Suppl 1():18-25. PubMed ID: 16633860
    [Abstract] [Full Text] [Related]

  • 7. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG, Gupta AK, Cherman AM, Inniss KA.
    J Cutan Med Surg; 2007 Dec 13; 11(3):99-122. PubMed ID: 17511926
    [Abstract] [Full Text] [Related]

  • 8. The effect of weight on the efficacy of biologic therapy in patients with psoriasis.
    Clark L, Lebwohl M.
    J Am Acad Dermatol; 2008 Mar 13; 58(3):443-6. PubMed ID: 18083274
    [Abstract] [Full Text] [Related]

  • 9. Biologicals in the treatment of psoriasis.
    Boker A, Kimball AB, Rolz-Cruz G.
    Curr Opin Investig Drugs; 2007 Nov 13; 8(11):939-46. PubMed ID: 17979028
    [Abstract] [Full Text] [Related]

  • 10. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR.
    J Dermatolog Treat; 2011 Apr 13; 22(2):65-74. PubMed ID: 20443663
    [Abstract] [Full Text] [Related]

  • 11. Practical understanding of mean percent psoriasis area and severity index reduction for biologics.
    English PL, Vender R.
    J Cutan Med Surg; 2008 Apr 13; 12(6):282-7. PubMed ID: 19317950
    [Abstract] [Full Text] [Related]

  • 12. Biologic agents in the treatment of psoriasis.
    Guarneri F, Guarneri C, Guarneri B.
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov 13; 1(3):193-217. PubMed ID: 19075983
    [Abstract] [Full Text] [Related]

  • 13. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
    Katugampola RP, Lewis VJ, Finlay AY.
    Br J Dermatol; 2007 May 13; 156(5):945-50. PubMed ID: 17388922
    [Abstract] [Full Text] [Related]

  • 14. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ, Bello-Quintero CE.
    J Manag Care Pharm; 2004 May 13; 10(4):318-25. PubMed ID: 15298530
    [Abstract] [Full Text] [Related]

  • 15. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
    Papp KA, Dekoven J, Parsons L, Pirzada S, Robern M, Robertson L, Tan JK.
    J Cutan Med Surg; 2012 May 13; 16(3):153-68. PubMed ID: 22713438
    [Abstract] [Full Text] [Related]

  • 16. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
    Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V, Lynde C, Murray E, Papp K, Poulin Y, Zip C.
    J Cutan Med Surg; 2004 May 13; 8(5):321-37. PubMed ID: 15868311
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH.
    Br J Dermatol; 2009 Jun 13; 160(6):1264-72. PubMed ID: 19120346
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.